Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Hologic HOLX is set to release third-quarter fiscal 2025 results on July 30, after the closing bell. The Zacks Consensus Estimate for third-quarter earnings per share (EPS) suggests a 0.9% decrease ...

Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Thursday after market hours. Here’s what you ...

I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay menu ...

The valuation also compares favorably to peers QIAGEN QGEN and Abbott ABT, which have a P/S of 3.30X and 2.50X, respectively. Still, the stock trades at a premium to the broader Medical sector’s ...

Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio ...

The market awaits Hologic's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to ...

Private equity firms TPG and Blackstone (NYSE:BX) recently bid to acquire Hologic Inc. (NASDAQ:HOLX), valuing the U.S. medical technology company at over $16 billion. Hologic is an American medical ...

MARLBOROUGH - Hologic, Inc. (NASDAQ:HOLX) reported fiscal first quarter earnings that fell short of analyst expectations, with revenue of $1.05 billion missing the consensus estimate of $1.07 billion.